Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03753919
Title Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol de Tumores Neuroendocrinos
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.